Utilization, reimbursement, and price trends for Hepatitis C virus medications in the US Medicaid programs: 2001–2021

Utilization, reimbursement, and price trends for Hepatitis C virus medications in the US Medicaid programs: 2001–2021

Background: Hepatitis C Virus (HCV) remains a challenging health problem worldwide, with increasing incidence despite being curable with Direct Acting Antiviral (DAA) agents. Objective: This study aimed to describe the utilization, reimbursement, and price trends of HCV treatments and evaluate the i...

Full description

Bibliographic Details
Main Authors: Musaab H. Gari, Abdulrahman Alsuhibani, Amin Alashgar, Jeff J. Guo
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Exploratory Research in Clinical and Social Pharmacy
Subjects:
Hepatitis C virus
Direct acting antivirals
Specialty medications
Medicaid
Utilization
Reimbursement
Online Access:http://www.sciencedirect.com/science/article/pii/S2667276623001646

Internet

http://www.sciencedirect.com/science/article/pii/S2667276623001646

Similar Items